These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34489274)

  • 1. Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial.
    Nyang'wa BT; Kloprogge F; Moore DAJ; Bustinduy A; Motta I; Berry C; Davies GR
    BMJ Open; 2021 Sep; 11(9):e047185. PubMed ID: 34489274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO.
    Stringer B; Lowton K; James N; Nyang'wa BT
    BMJ Open; 2021 Sep; 11(9):e043954. PubMed ID: 34489263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy.
    Sweeney S; Gomez G; Kitson N; Sinha A; Yatskevich N; Staples S; Moodliar R; Motlhako S; Maloma M; Rassool M; Ngubane N; Ndlovu E; Nyang'wa BT
    BMJ Open; 2020 Oct; 10(10):e036599. PubMed ID: 33039989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
    Davies Forsman L; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar JW; Mansjö M; Hoffner S; Xu B; Schön T; Bruchfeld J
    BMJ Open; 2018 Oct; 8(9):e023899. PubMed ID: 30287613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
    Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
    BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study.
    Kloprogge F; Abubakar I; Esmail H; Hack V; Kunst H; McHugh TD; Noursadeghi M; Surey J; Tiberi S; Lipman M
    BMJ Open; 2021 Jul; 11(7):e052885. PubMed ID: 34244287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing new mHealth technologies to Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial.
    Velen K; Nguyen VN; Nguyen BH; Dang T; Nguyen HA; Vu DH; Do TT; Pham Duc C; Nguyen HL; Pham HT; Marais BJ; Johnston J; Britton W; Beardsley J; Negin J; Wiseman V; Marks GB; Nguyen TA; Fox GJ
    BMJ Open; 2022 Jun; 12(6):e052633. PubMed ID: 35732397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
    Fox GJ; Nguyen CB; Nguyen TA; Tran PT; Marais BJ; Graham SM; Nguyen BH; Velen K; Dowdy DW; Mason P; Britton WJ; Behr MA; Benedetti A; Menzies D; Nguyen VN; Marks GB
    BMJ Open; 2020 Jan; 10(1):e033945. PubMed ID: 31900274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy and consequences of using
    Divala TH; Fielding KL; Sloan DJ; French N; Nliwasa M; MacPherson P; Kandulu CC; Chiume L; Chilanga S; Ndaferankhande MJ; Corbett EL
    BMJ Open; 2020 Mar; 10(3):e033999. PubMed ID: 32217561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial.
    Rosu L; Madan J; Worrall E; Tomeny E; Squire B;
    BMJ Open; 2020 Dec; 10(12):e042390. PubMed ID: 33371043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.
    van den Elsen SH; Sturkenboom MG; Akkerman O; Barkane L; Bruchfeld J; Eather G; Heysell SK; Hurevich H; Kuksa L; Kunst H; Kuhlin J; Manika K; Moschos C; Mpagama SG; Muñoz Torrico M; Skrahina A; Sotgiu G; Tadolini M; Tiberi S; Volpato F; van der Werf TS; Wilson MR; Zúñiga J; Touw DJ; Migliori GB; Alffenaar JW
    BMJ Open; 2020 Jun; 10(6):e035350. PubMed ID: 32554740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
    Metcalfe J; Bacchetti P; Esmail A; Reckers A; Aguilar D; Wen A; Huo S; Muyindike WR; Hahn JA; Dheda K; Gandhi M; Gerona R
    BMC Infect Dis; 2021 Jan; 21(1):99. PubMed ID: 33482745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
    Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where there is hope: a qualitative study examining patients' adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Horter S; Stringer B; Greig J; Amangeldiev A; Tillashaikhov MN; Parpieva N; Tigay Z; du Cros P
    BMC Infect Dis; 2016 Jul; 16():362. PubMed ID: 27465783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.
    Yang M; Pan H; Lu L; He X; Chen H; Tao B; Liu W; Yi H; Tang S
    BMJ Open; 2019 Mar; 9(3):e027321. PubMed ID: 30928962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
    Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
    Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.